Welcome to our dedicated page for Revolution SEC filings (Ticker: RVMDW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Revolution's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Revolution's regulatory disclosures and financial reporting.
Revolution Medicines, Inc. reported that director Kim Lorence H. received new equity compensation awards. The director was granted 1,191 shares of Common Stock in the form of restricted stock units at no cash cost, increasing direct holdings to 74,281 shares. In addition, the director received a stock option for 3,127 shares of Common Stock with an exercise price of $162.99 per share, expiring on June 18, 2036. The option vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting after the grant date, as long as the director continues as a service provider under the company’s 2020 Plan.
Revolution Medicines, Inc. reported that director Kim Lorence H. received new equity compensation awards. The director was granted 1,191 shares of Common Stock in the form of restricted stock units at no cash cost, increasing direct holdings to 74,281 shares. In addition, the director received a stock option for 3,127 shares of Common Stock with an exercise price of $162.99 per share, expiring on June 18, 2036. The option vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting after the grant date, as long as the director continues as a service provider under the company’s 2020 Plan.
Revolution Medicines director Alexis Borisy reported equity awards from the company. He received 1,191 shares of Common Stock as a grant, bringing his direct holdings to 2,340,075 shares after the transaction. He was also granted options to purchase 3,127 shares of Common Stock at an exercise price of $162.99 per share, expiring on June 18, 2036.
The 1,191 granted shares are structured as restricted stock units. The option will vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting after the grant date, as long as Borisy continues as a Service Provider under the company’s 2020 Plan.
Revolution Medicines director Alexis Borisy reported equity awards from the company. He received 1,191 shares of Common Stock as a grant, bringing his direct holdings to 2,340,075 shares after the transaction. He was also granted options to purchase 3,127 shares of Common Stock at an exercise price of $162.99 per share, expiring on June 18, 2036.
The 1,191 granted shares are structured as restricted stock units. The option will vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting after the grant date, as long as Borisy continues as a Service Provider under the company’s 2020 Plan.
Revolution Medicines director Elizabeth M. Anderson reported compensation-related equity grants and updated holdings. She received 1,191 shares of common stock as a grant of restricted stock units and a stock option for 3,127 shares at an exercise price of $162.99 per share.
The option covers 3,127 shares of common stock and expires on June 18, 2036. These option shares vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting after the grant date, assuming she continues as a service provider.
After these awards, Anderson directly holds 9,406 shares of common stock, which include the 1,191 restricted stock units. Separately, 26,990 shares of common stock are held indirectly through the David W. Anderson 1996 Irrevocable Trust.
Revolution Medicines director Elizabeth M. Anderson reported compensation-related equity grants and updated holdings. She received 1,191 shares of common stock as a grant of restricted stock units and a stock option for 3,127 shares at an exercise price of $162.99 per share.
The option covers 3,127 shares of common stock and expires on June 18, 2036. These option shares vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting after the grant date, assuming she continues as a service provider.
After these awards, Anderson directly holds 9,406 shares of common stock, which include the 1,191 restricted stock units. Separately, 26,990 shares of common stock are held indirectly through the David W. Anderson 1996 Irrevocable Trust.
Revolution Medicines director Sandra Horning reported equity compensation awards. She received 1,191 shares of common stock at no cost, bringing her direct holdings to 97,765 shares, which include 6,083 restricted stock units. She was also granted a stock option for 3,127 shares at an exercise price of $162.99 per share, expiring on June 18, 2036.
The option vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting, as long as she continues to serve as a service provider under the company’s 2020 plan.
Revolution Medicines director Sandra Horning reported equity compensation awards. She received 1,191 shares of common stock at no cost, bringing her direct holdings to 97,765 shares, which include 6,083 restricted stock units. She was also granted a stock option for 3,127 shares at an exercise price of $162.99 per share, expiring on June 18, 2036.
The option vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting, as long as she continues to serve as a service provider under the company’s 2020 plan.
Revolution Medicines director Frank Clyburn reported receiving equity awards in the form of common stock and stock options. He was granted 1,191 shares of Common Stock, increasing his direct holdings to 10,929 shares, and a separate grant of 3,127 Stock Options (Right to Buy) with a $162.99 exercise price, each option for one share of common stock.
The option grant will vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next annual meeting following the grant date, as long as he remains a Service Provider under the company’s 2020 Plan through that vesting date. The filing also notes that his holdings include 4,080 restricted stock units, which typically convert into shares over time.
Revolution Medicines director Frank Clyburn reported receiving equity awards in the form of common stock and stock options. He was granted 1,191 shares of Common Stock, increasing his direct holdings to 10,929 shares, and a separate grant of 3,127 Stock Options (Right to Buy) with a $162.99 exercise price, each option for one share of common stock.
The option grant will vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next annual meeting following the grant date, as long as he remains a Service Provider under the company’s 2020 Plan through that vesting date. The filing also notes that his holdings include 4,080 restricted stock units, which typically convert into shares over time.
Revolution Medicines, Inc. director Sushil Patel reported equity awards consisting of common stock and stock options. He received 1,191 shares of Common Stock, which include 1,191 restricted stock units. Following this award, he directly holds 24,281 common shares.
He also received a stock option covering 3,127 shares of Common Stock at an exercise price of $162.99 per share, expiring on June 18, 2036. The option vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the annual meeting following the grant date, subject to his continued service.
Revolution Medicines, Inc. director Sushil Patel reported equity awards consisting of common stock and stock options. He received 1,191 shares of Common Stock, which include 1,191 restricted stock units. Following this award, he directly holds 24,281 common shares.
He also received a stock option covering 3,127 shares of Common Stock at an exercise price of $162.99 per share, expiring on June 18, 2036. The option vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the annual meeting following the grant date, subject to his continued service.
Revolution Medicines director Flavia Borellini received new equity awards. She was granted 1,191 shares of common stock in the form of Restricted Stock Units, increasing her direct holdings to 26,215 common shares. She also received a stock option for 3,127 shares at an exercise price of $162.99 per share, expiring on June 18, 2036. The option vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting after the grant date, as long as she remains a service provider under the company’s 2020 Plan.
Revolution Medicines director Flavia Borellini received new equity awards. She was granted 1,191 shares of common stock in the form of Restricted Stock Units, increasing her direct holdings to 26,215 common shares. She also received a stock option for 3,127 shares at an exercise price of $162.99 per share, expiring on June 18, 2036. The option vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting after the grant date, as long as she remains a service provider under the company’s 2020 Plan.
Revolution Medicines announced that Steve Kelsey, M.D., will retire from his employment effective January 4, 2027. He will transition from president, research and development to senior advisor to the chief executive officer on July 1, 2026, and the company contemplates appointing him to its board of directors at retirement, subject to board approval.
The company also reported results from its annual meeting of stockholders. Stockholders elected Class III directors Alexis Borisy and Mark A. Goldsmith, M.D., Ph.D., to terms ending at the 2029 annual meeting. They ratified PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026, and approved, on a non-binding advisory basis, the compensation of named executive officers.
Revolution Medicines announced that Steve Kelsey, M.D., will retire from his employment effective January 4, 2027. He will transition from president, research and development to senior advisor to the chief executive officer on July 1, 2026, and the company contemplates appointing him to its board of directors at retirement, subject to board approval.
The company also reported results from its annual meeting of stockholders. Stockholders elected Class III directors Alexis Borisy and Mark A. Goldsmith, M.D., Ph.D., to terms ending at the 2029 annual meeting. They ratified PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026, and approved, on a non-binding advisory basis, the compensation of named executive officers.
Revolution Medicines executive Anthony Mancini reported an automatic sale of shares to cover taxes on vested stock units. On the transaction date, 4,615 shares of common stock were sold in open-market trades at a weighted average price of $156.1192 per share.
The filing explains that this was an automatic sell-to-cover solely for applicable withholding taxes following restricted stock unit vesting, rather than a discretionary sale. After the transaction, Mancini held 49,975 shares directly, including 43,700 restricted stock units and 190 shares acquired under the company’s Employee Stock Purchase Plan.
Revolution Medicines executive Anthony Mancini reported an automatic sale of shares to cover taxes on vested stock units. On the transaction date, 4,615 shares of common stock were sold in open-market trades at a weighted average price of $156.1192 per share.
The filing explains that this was an automatic sell-to-cover solely for applicable withholding taxes following restricted stock unit vesting, rather than a discretionary sale. After the transaction, Mancini held 49,975 shares directly, including 43,700 restricted stock units and 190 shares acquired under the company’s Employee Stock Purchase Plan.
Revolution Medicines director and officer Mark A. Goldsmith reported an open-market sale of 10,020 shares of common stock on June 16, 2026 at a weighted average price of $156.1188 per share. The transaction was executed under a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy tax withholding obligations from restricted stock unit vesting.
Following this sale, Goldsmith directly holds 267,330 shares of Revolution Medicines common stock, which includes 182,938 restricted stock units and 652 shares acquired under the company’s Employee Stock Purchase Plan. He also has additional indirect holdings through family revocable trusts.
Revolution Medicines director and officer Mark A. Goldsmith reported an open-market sale of 10,020 shares of common stock on June 16, 2026 at a weighted average price of $156.1188 per share. The transaction was executed under a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy tax withholding obligations from restricted stock unit vesting.
Following this sale, Goldsmith directly holds 267,330 shares of Revolution Medicines common stock, which includes 182,938 restricted stock units and 652 shares acquired under the company’s Employee Stock Purchase Plan. He also has additional indirect holdings through family revocable trusts.